compounded semaglutide risks Patient Safety Updates FDA Warns on Certain Forms

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily prescribed for type 2 diabetes management and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities

Limited Long-Term Data Mounjaro only approved in 2022 Zepbound only approved in 2023 Long-term safety profile still emerging Unknown effects of decades-long use 2

The pipeline data below are compiled from the Synapse database: In addition to single GLP-1R targets, GLP-1R combined with multi-target therapies has become a major direction in clinical development

Boden G, Homko C, Barrero CA, Stein TP, Chen X, Cheung P, et al

This includes eating better and exercising regularly

Its important to work with them to ensure youre starting at the right dose and learn whether it will interfere with other medications or if you are predisposed to adverse effects, she says